Skip to search formSkip to main contentSkip to account menu

PEGylated soluble tumor necrosis factor receptor I

Known as: PEG sTNFRI, Pegsunercept 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Polyethylene Glycolstumor necrosis factor receptor 1A

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Induction of immune tolerance to rat liver allograft by sTNFRI-IgGFc and CCR 7 gene modified immature dendritic cells
Background: Dendritic cells (DC) are the most powerful antigen presenting cells, which play key roles in recognition and… 
Highly Cited
2015
Highly Cited
2015
Diabetes reduces mesenchymal stem cells in fracture healing through a TNFα-mediated mechanism
Aims/hypothesisDiabetes interferes with bone formation and impairs fracture healing, an important complication in humans and… 
2008
2008
[Construction of adenoviral vector encoding soluble human sTNFRI-IgGFc cDNA and its expression in human airway smooth muscle cells (HASMCs)].
Tumour necrosis factor (TNF-a) is a pro-inflammatory cytokine that has been implicated in many aspects of the airway pathology in… 
2007
2007
Citocinas y otros parámetros inmunológicos como marcadores de alteración de órganos a distancia en la pancreatitis aguda
Fundamento y objetivo: Es conocido el papel que desempenan los mediadores inmunologicos proinflamatorios en la patogenia de… 
2006
2006
Antiferritin antibodies are potential biomarkers for rheumatoid arthritis
2006
2006
Pegsunercept is a safe and efficacious treatment for rheumatoid arthritis
Preclinical studies have indicated that pegsunercept, a polyethylene-glycol-modified soluble tumor-necrosis-factor receptor type… 
2006
2006
More support for MRI-based screening of joint damage in rheumatoid arthritis
Preclinical studies have indicated that pegsunercept, a polyethylene-glycol-modified soluble tumor-necrosis-factor receptor type… 
2005
2005
A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis.
OBJECTIVE In a phase 2 study, to assess the efficacy and safety of pegsunercept, a soluble tumor necrosis factor receptor type I… 
2005
2005
Novel pharmaceutical compositions based on anticholinergics and pegsunercept
The present invention relates to novel pharmaceutical compositions based on the anticholinergic and PEGSUNERCEPT, the use of said… 
2003
2003
Pegsunercept: Anticytokine therapy treatment of rheumatoid arthritis
Standard pharmacological interventions in rheumatoid arthritis involve administration of nonsteroidal antiinflammatory drugs… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)